Hi Susan,

Reading your post just re-emphasizes the major concern I've always had with this drug...and that is the way Biogen/Elan rushed its introduction into the marketplace!

Even though they were aware of the dangers of a monoclonal antibody and certainly didn't have any kind of reliable safety data, Biogen/Elan focused solely on the so-called beneficial stats of Tysabri from one year data from 2 of 99 world-wide Phase III trials going on at that time. That's what they used to convince the FDA to accelerate the approval of the drug while at the same time making several press releases on how wonderful this drug was going to be for all MS patients. The problems that were happening were swept under the carpet and got little if any attention.

I really hope that MS patients don't pay the price for this kind of drug marketing.

Harry